Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis

PURPOSE: Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition of the KRAS pathway with the MEK inhibitor trametinib would inhibit the outgrowth of occult...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Surg Oncol
Hlavní autoři: Newhook, Timothy E., Lindberg, James M., Adair, Sara J., Kim, Alison J., Stelow, Edward B., Rahma, Osama E., Parsons, J. Thomas, Bauer, Todd W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637098/
https://ncbi.nlm.nih.gov/pubmed/26847682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-016-5116-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky